

Diaceutics awarded UK Research Institute Grant Funding of £1m

Belfast and London, 5 December 2024 - [Diaceutics PLC](#) (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce that the Company has been awarded approximately £1m in grant funding from the United Kingdom Research Institute (UKRI) Strength in Places Fund, to further elucidate the gaps in clinical practices that need addressing so that all appropriate patients benefit from precision medicine in Northern Ireland/UK. An output of this grant is expected to be enhancements to Diaceutics' data products in 2025.

Diaceutics' is proud to be a partner with many great Northern Ireland institutions and companies that collectively support and enhance the Belfast medical & technology community, which is critical for sustainable talent development in the region.

The UKRI Strength in Places Fund, via its Wave 2 investment phase, will provide £34m to fund the Future Medicines Institute based at Queens University Belfast and its purpose will be to provide infrastructure & expertise to Northern Ireland based companies and to act as a research accelerator unit.

Ryan Keeling, Chief Executive Officer of Diaceutics, commented: *"We are very grateful to the UKRI for awarding this funding, which we will deploy to support our R&D activities. Initiatives such as this are very important and will help us progress our data products, clinical data & bioinformatics pipeline development, staff skills and apprenticeships development".*

**Enquiries:
Diaceutics PLC**

Ryan Keeling, Chief Executive Officer
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com

Canaccord Genuity Limited (Nomad & Broker)

Simon Bridges, Andrew Potts, Harry Rees

Tel: +44 (0)20 7523 8000

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFLFESFRLVIIS